Literature DB >> 17549355

The effect of chemotherapy on Ki-67, Bcl-2 and Bak expression in primary tumors and lymph node metastases of breast cancer.

Mariusz Koda1, Mariola Sulkowska, Luiza Kanczuga-Koda, Jakub Tomaszewski, Waldemar Kucharczuk, Tomasz Lesniewicz, Slawomir Cymek, Stanislaw Sulkowski.   

Abstract

The aim of this study was the analysis of Ki-67, Bcl-2 and Bak expression in primary tumor and axillary lymph node metastases of breast cancer as well as an attempt to assess preoperative chemotherapy influence on the mentioned markers with regard to changes in the morphological appearance of the primary tumor and its metastases. Immunohistochemical examinations of Ki-67, Bcl-2 and Bak expression were conducted on sections collected from 135 patients treated surgically on invasive ductal breast cancer. Sixty-four of these patients were administered preoperative chemotherapy, whilst on 71 patients the surgery was performed without initial chemotherapy. In the group of patients without preoperative chemotherapy positive correlation in Ki-67 and Bcl-2 expression between primary tumors and lymph node metastases (p<0.0001, r=0.707; p<0.0001, r=0.604, respectively) was observed. In the group of patients after chemotherapy positive correlation between primary tumors and lymph node metastases in case of Bcl-2 and Bak proteins (p<0.04, r=0.424; p<0.02, r=0.478, respectively) was observed. It was also found that preoperative chemotherapy has an influence on the expression of proteins connected with proliferation and apoptosis and thus, it can influence neoplastic process biology. It does not have any significant impact on the proapoptotic Bak protein expression either in primary tumor or in lymph node metastases of breast cancer. However, it is related to lower expression of antiapoptotic Bcl-2 protein (p<0.0005) and of Ki-67 proliferation marker (p<0.03) in primary tumors, which indirectly indicates a beneficial influence of preoperative chemotherapy on the primary tumor. Concurrently, the influence of neoadjuvant therapy on lymph node metastases seems to be relatively small, which can limit its effectiveness.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17549355

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  ERα and ERβ expression in correlation with Ki-67, Bcl-2 and Bak in primary tumors and lymph node metastases of breast cancer: The effect of pre-operative chemotherapy.

Authors:  Luiza Kanczuga-Koda; Mariusz Koda; Jakub Tomaszewski; Katarzyna Jarzabek; Joanna Lotowska; Marek Baltaziak; Urszula Sulkowska; Maria Sobaniec-Lotowska; Stanisław Sulkowski
Journal:  Oncol Lett       Date:  2010-09-23       Impact factor: 2.967

2.  Prognostic Value of Receptor Change After Neoadjuvant Chemotherapy in Breast Cancer Patients.

Authors:  Özlem Özdemir; Baha Zengel; Demet Kocatepe Çavdar; Cengiz Yılmaz; Raika Durusoy
Journal:  Eur J Breast Health       Date:  2022-04-01

3.  Relationships between hypoxia markers and the leptin system, estrogen receptors in human primary and metastatic breast cancer: effects of preoperative chemotherapy.

Authors:  Mariusz Koda; Luiza Kanczuga-Koda; Mariola Sulkowska; Eva Surmacz; Stanislaw Sulkowski
Journal:  BMC Cancer       Date:  2010-06-22       Impact factor: 4.430

4.  The effects of phenoxodiol on the cell cycle of prostate cancer cell lines.

Authors:  Simon Mahoney; Frank Arfuso; Michael Millward; Arun Dharmarajan
Journal:  Cancer Cell Int       Date:  2014-11-08       Impact factor: 5.722

5.  Mammaglobin-A, VEGFR3, and Ki67 in Human Breast Cancer Pathology and Five Year Survival.

Authors:  Elizabeth Baker; Naomi Whiteoak; Louise Hall; James France; Deborah Wilson; Pudupalayam Bhaskar
Journal:  Breast Cancer (Auckl)       Date:  2019-06-26

6.  Evaluation of Tumor Cell Proliferation by Ki-67 Expression and Mitotic Count in Lymph Node Metastases from Breast Cancer.

Authors:  Sura Aziz; Elisabeth Wik; Gøril Knutsvik; Tor Audun Klingen; Ying Chen; Benedicte Davidsen; Hans Aas; Turid Aas; Lars A Akslen
Journal:  PLoS One       Date:  2016-03-08       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.